Melanie M. Frigault - Vincerx Pharma, Inc.

基本信息

浏览量：0

职业迁徙

个人简介

Proven track record of strategic and scientific leadership to deliver decision making biomarker data for dose and schedule selection, understanding mechanisms of resistance for rationale-based combinations and to select the right patient/indication for pipeline clinical development.

研究兴趣

论文共 97 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Abstract 629: Activity of VIP943 on AML Patient-Derived Leukemic Blasts and Healthy Donor-Derived Bone Marrow Hematopoietic Stem Cells

Beatrix Stelte-Ludwig,Tibor Schomber,Melanie M. Frigault,Joseph Birkett,Amy J. Johnson,Anne-Sophie Rebstock, Sebastian Ludwig,Raquel Izumi,Ahmed Hamdy

Cancer Researchno. 6_Supplement (2024): 629-629

引用0浏览0引用

Enitociclib, a Selective CDK9 Inhibitor: in Vitro and in Vivo Preclinical Studies in Multiple Myeloma

Son Tran, Patrick Sipila,Melanie M. Frigault, Beatrix Stelte-Ludwig, Amy J. Johnson,Joseph Birkett,Raquel Izumi, Ahmed Hamdy,Ranjan Maity,Nizar J. Bahlis, Paola Neri,Aru Narendran

Blood Neoplasia (2024)

引用0浏览0引用

An Open-Label, Multicenter Phase 1 Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity, Pharmacokinetics, and Pharmacodynamics of VIP943 Monotherapy in Patients with Advanced CD123+ Hematologic Malignancies

Stephen Anthony Strickland, Emily K. Curran, Omer Hassan Jamy, Mary-Elizabeth Percival, Amy J. Johnson,Joseph Birkett,Xin Huang,Melanie M. Frigault, Hans-Georg Lerchen, Beatrix Stelte-Ludwig, Tasheda Navarro, Jim Peck, Wyatt Gross,Raquel Izumi, Ahmed M. Hamdy,Naval Guastad Daver

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2024)

引用0浏览0引用

An Open-Label, Multicenter Phase 1 Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity, and Pharmacokinetics of VIP236 Monotherapy in Patients with Advanced Cancer

Andrae L. Vandross, Brian N. Stein, Jermaine Coward,Sunil Sharma, Amy J. Johnson,Joseph Birkett,Xin Huang,Melanie M. Frigault, Hans-Georg Lerchen, Beatrix Stelte-Ludwig, Tasheda Navarro, Jim Peck, Wyatt Gross,Raquel Izumi, Ahmed M. Hamdy, Ildefonso Rodriguez Rivera

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2024)

引用0浏览0引用

Table S2 from Enitociclib, a Selective CDK9 Inhibitor, Induces Complete Regression of MYC+ Lymphoma by Downregulation of RNA Polymerase II Mediated Transcription